en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background:</span></span></span></span></span></span> <span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">To evaluate the clinical effectiveness of autologous peripheral blood hematopoietic stem cell transplantation (Auto-HSCT) as a therapeutic approach for patients with both refractory systemic sclerosis (SSc) and cancer undergoing radiotherapy. </span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-GB">Materials and Methods: </span></span></span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">Eleven patients with refractory SSc and concurrent cancer received Auto-HSCT following peripheral blood stem cell mobilization. Standardized radiotherapy protocols were applied based on cancer type. Preconditioning regimens included combinations of cyclophosphamide, melphalan, rituximab, and bendamustine. Post-transplant assessments focused on hematopoietic recovery, SSc disease activity, and tumor response. </span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-GB">Results: </span></span></span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">A mean of 3.87 &times; 10</span></span></span></span><span lang="en-GB" style="font-size:5.9939pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">⁶</span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">/kg CD34+ cells were collected. All patients achieved hematopoietic reconstitution, with neutrophil and platelet recovery occurring in 9 &plusmn; 3 and 14 &plusmn; 7 days, respectively. At a median follow-up of 14.6 months, improvements in modified Rodnan skin scores (mRSS), digital ulcers, Raynaud&rsquo;s phenomenon, and pulmonary fibrosis were observed. Eight patients showed sustained improvement in SSc and cancer response. Three patients relapsed and required additional immunotherapy. </span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-GB">Conclusion: </span></span></span></span></span></span><span lang="en-GB" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-GB">Auto-HSCT appears to be a feasible and effective option for patients with both refractory SSc and cancer undergoing radiotherapy. It improved autoimmune disease control, enhanced hematopoietic recovery, and supported cancer treatment with manageable toxicity.</span></span></span></span></span></span></span></span></span></span></div> Systemic Sclerosis, Neoplasms, Radiotherapy, Hematopoietic Stem Cell Transplantation, Autologous, CD34 Antigen. 173 178 http://ijrr.com/browse.php?a_code=A-10-1-1472&slc_lang=en&sid=1 S. Tong 7900319475328460032905 7900319475328460032905 No Department of Hematology, Rheumatology and Immunology, Pu'er People's Hospital, Pu’er, China Z. Liu 7900319475328460032906 7900319475328460032906 No Department of Hematology, Rheumatology and Immunology, Pu'er People's Hospital, Pu’er, China Q. Wen 7900319475328460032907 7900319475328460032907 No Hematology Center, Second Affiliated Hospital of Army Medical University, Chongqing, China X. Zhang 7900319475328460032908 7900319475328460032908 No Hematology Center, Second Affiliated Hospital of Army Medical University, Chongqing, China C. Zheng onrx855@163.com 7900319475328460032909 7900319475328460032909 Yes Department of Hematology, Rheumatology and Immunology, Pu'er People's Hospital, Pu’er, China